Survey on Epidemiology of Hypoparathyroidism in France
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No intervention.
- Who it may be relevant to
- Registry conditions: Hypoparathyroidism. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France
Overview
Very few data has been published on the epidemiology of hypoparathyroidism worldwide: none exists specifically for France. Hypoparathyroidism could led to complications. Here, the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Detailed description
Very few data has been published on the epidemiology of hypoparathyroidism worldwide. None exists specifically in France. Hypoparathyroidism could led to complications: e.g. symptomatic hypocalcemia, calcifications (brain, eye and other soft tissues), nephrolithiasis/nephrocalcinosis, renal insufficiency. Here,the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Interventions
- Other No intervention
No intervention
Primary outcome measures
- Assessment of the epidemiology of patients with hypoparathyroidism in France [Time frame: Through study completion, about 2 years]
Secondary outcome measures (3)
- Assessment of the biology at inclusion will describe the evolution of the included population from diagnosis to now (inclusion) [Time frame: At inclusion (under treatment): through study completion, about 2 years]
- Assessment of the management at inclusion will describe treatment and complications at inclusion [Time frame: At inclusion (under treatment): through study completion, about 2 years]
- Assessment of the biology (calcemia, calciuria, parathormone, creatininemia, phosphatemia & magnesemia) at diagnosis and drug therapy at inclusion will describe population [Time frame: Through study completion, about 2 years]
Eligibility criteria
Inclusion criteria
- patient fro whom chronic hypoparathyroidism is diagnosed
- patient living in France
Exclusion criteria
- patient who does not want his data to be collected in this registry
- pseudo-hypoparathyroidism
- acute hypoparathyroidism
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 57 centers
- Felix Guyon Hospital — Saint-Denis
- Hôpital Privé de Provence — Aix-en-Provence
- Amiens University Hospital — Amiens
- Clinic Auch Area — Auch
- Henri Mondor Hospital — Aurillac
- Jean Minjoz Hospital — Besançon
- Blanquefort — Blanquefort
- Avicenne Hospital, AP-HP — Bobigny
- … and 49 more centers
Publications
- Bertocchio JP, Grosset N, Groussin L, Kamenicky P, Larceneux F, Lienhardt-Roussie A, Linglart A, Maruani G, Mirallie E, Pattou F, Seervai RNH, Sido C, Silve C, Vilfaillot A, Tabarin A, Vantyghem MC, Houillier P. Practice patterns for chronic hypoparathyroidism: data from patients and physicians in France. Endocr Connect. 2022 Jan 31;11(1):e210350. doi: 10.1530/EC-21-0350. PMID 34939939
Identifiers
NCT: NCT02838927 · EpiHypo